Economic Evaluation of Glucosamine in Knee Osteoarthritis Treatments in Vietnam

Osteoarthritis (OA) is the degeneration of cartilage in joints that results in bones rubbing against each other; it causes uncomfortable symptoms such as pain, swelling, and stiffness and can lead to disability. It usually occurs in the elderly and causes a large medical burden. The aim of this stud...

Full description

Saved in:
Bibliographic Details
Published in:Healthcare (Basel) 2023-09, Vol.11 (18), p.2502
Main Authors: Vo, Nam Xuan, Che, Uyen Thi Thuc, Ngo, Thanh Thi Thanh, Bui, Tien Thuy
Format: Article
Language:English
Subjects:
Analgesics
Anti-inflammatory agents
Antiarthritic agents
Arthritis
Bones
Care and treatment
Cartilage
Complications and side effects
Cost analysis
cost-utility analysis
Development and progression
Diagnosis
economic evaluation
Etoricoxib
Glucosamine
Inflammation
Joint surgery
Knee
knee osteoarthritis
Lifestyles
Nonsteroidal anti-inflammatory drugs
Osteoarthritis
Pain
Patient outcomes
Quality of life
Risk factors
Steroids
Sulfates
Vietnam
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Osteoarthritis (OA) is the degeneration of cartilage in joints that results in bones rubbing against each other; it causes uncomfortable symptoms such as pain, swelling, and stiffness and can lead to disability. It usually occurs in the elderly and causes a large medical burden. The aim of this study is to evaluate the cost-effectiveness between the standard treatment for osteoarthritis and standard treatment with added crystalline glucosamine sulfate at various stages. Markov analysis modeling was applied to evaluate the effect of both adding glucosamine compared to standard treatment from a societal perspective during whole patients’ lifetimes. Data input was collected from reviews in previous studies. The outcome was measured in quality-adjusted life years (QALYs), and the Incremental Cost-Effectiveness Ratio (ICER) from a societal perspective was applied with 3% and discounted for all costs and outcomes. One-way analysis via the Tornado diagram was performed to investigate the change in factors in the model. In general, adding glucosamine into the standard treatment proved to be more cost-effective compared to the standard treatment. Particularly, the early-stage addition of glucosamine in the treatment was cost-effective compared to the post-stage addition of glucosamine. The addition of supplementing crystalline glucosamine sulfate to the whole regimen at any stage was cost-effective at the willingness-to-pay (WTP) threshold.
ISSN:2227-9032
2227-9032
DOI:10.3390/healthcare11182502